



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

1. Name of Inspector from whom received : P Lalitanzova, Asst Drugs Inspector (F & D), CMO Office, Lawngtlai
2. Serial No. and date of Inspector's memorandum : 4/DS/LTI/24 Date 21.02. 2025
3. Number of Sample : Nil
4. Date of receipt : 05-MAR-2025
5. Names of drugs purporting to be contained in the sample: Calcium & Vitamin D3 Tablets I.P. (Caldicare)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2025-26/0302	GUW/LS/2025-26/306	MT-24023	JAN. 2024 DEC. 2025	NA	Medimark Drugs & Pharmaceuticals Plot No.39, Sector 6A, IIE, SIDCUL Haridwar-249403 (U.K.)

6. Condition of seals on : Seals were intact & identical to the Specimen impression of the seal received from Drugs Inspector
[the packet or on portion of sample or container]

7. Result of test or analysis with protocols or test or analysis applied : Please see below

Date of Testing : From 20-May-2025 To 28-May-2025

COMPOSITION :

Each film coated tablet contains:
1250 mg of Calcium Carbonate from organic source (Oyster Shell)
eq. to elemental Calcium 500 mg
Vitamin D3 I.P. 250 I.U.

Protocol Applied: I.P. 2022

Sr No.	Test Name	Result	Limits
1	Description	Blue colour, elongated, bi-convex, film coated tablet having a dosage line on one side in blister pack.	NA
2	Identification	Gives positive test for Calcium & Vitamin D3.	NA
3	Average weight	1.5471 gm.	NA
4	Uniformity of weight	Complies.	± 5%
5	Dissolution	Complies for Calcium at S ₂ stage (Avg. of 12 units (S ₁ +S ₂) is found > 'Q' 70% and no unit is found (<Q-15%).	Average of 12 units (S ₁ +S ₂) is ≥ 70% (≥Q) and no unit is < 55% of claim (Q-15%).

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method

1	Calcium Carbonate equivalent to elemental Calcium	500.67 mg/Tablet	500 mg/Tablet	100.134	90 % to 110 %	I.P. 2022
2	Vitamin D3	425.52 I.U./Tablet	250 I.U./Tablet	170.208	NLT 90 %	I.P. 2022

In the opinion of the under signed the sample referred to above **is of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules thereunder for the reasons given below:-

The sample conforms to I.P. with respect to the above tests only.

Date: 29-MAY-2025


GOVERNMENT ANALYST
Dilip Kr. Sarkar
Government Analyst
R.D.T.L., Guwahati-22

----- END OF REPORT -----

